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Abstract
Over the last fifteen years there have been five pandemics of norovirus (NoV) associated gastroenteritis, and the period of
stasis between each pandemic has been progressively shortening. NoV is classified into five genogroups, which can be
further classified into 25 or more different human NoV genotypes; however, only one, genogroup II genotype 4 (GII.4), is
associated with pandemics. Hence, GII.4 viruses have both a higher frequency in the host population and greater
epidemiological fitness. The aim of this study was to investigate if the accuracy and rate of replication are contributing to
the increased epidemiological fitness of the GII.4 strains. The replication and mutation rates were determined using in vitro
RNA dependent RNA polymerase (RdRp) assays, and rates of evolution were determined by bioinformatics. GII.4 strains were
compared to the second most reported genotype, recombinant GII.b/GII.3, the rarely detected GII.3 and GII.7 and as a
control, hepatitis C virus (HCV). The predominant GII.4 strains had a higher mutation rate and rate of evolution compared to
the less frequently detected GII.b, GII.3 and GII.7 strains. Furthermore, the GII.4 lineage had on average a 1.7-fold higher rate
of evolution within the capsid sequence and a greater number of non-synonymous changes compared to other NoVs,
supporting the theory that it is undergoing antigenic drift at a faster rate. Interestingly, the non-synonymous mutations for
all three NoV genotypes were localised to common structural residues in the capsid, indicating that these sites are likely to
be under immune selection. This study supports the hypothesis that the ability of the virus to generate genetic diversity is
vital for viral fitness.
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Introduction
Norovirus (NoV), a member of the Caliciviridae family, is now
considered the most common cause of viral gastroenteritis
outbreaks in adults worldwide [1]. In the US, NoV has been
identified as the cause of over 73% of outbreaks of gastroenteritis
[1]. Furthermore, outbreak NoV strains spread rapidly causing
great economic burden on society due to medical and social
expenses. Consequently, a vaccine or treatment for NoV would
be useful in reducing its transmission and alleviating disease
symptoms. Our current knowledge of NoV replication and
evolution has made it difficult to predict the efficacy of a
treatment or longevity of a vaccine, as evidence is emerging that
NoV, like many other RNA viruses, exists as a dynamic, rapidly
evolving and genetically diverse population [2,3,4]. The high
level of genetic diversity in RNA viruses is recognised as the basis
for their ubiquity and adaptability [5]. Therefore, in order to
develop a successful treatment or control program it is first
necessary to understand the mechanisms behind NoV replication
and evolution.
NoV is a small round virion of 27–38 nm in diameter and
possesses a single-stranded, positive-sense, polyadenylated, RNA
genome of 7400–7700 nucleotides [6]. The human NoV genome
is divided into three open reading frames (ORFs). ORF1 encodes
for the non-structural proteins, including an NTPase, 3C-like
protease and RNA-dependent RNA polymerase (RdRp) [7]. The
two structural proteins VP1, the major capsid protein, and VP2,
the minor capsid protein are encoded by ORF2 and ORF3,
respectively [8,9].
NoV is a highly diverse genus with up to 61% VP1 amino acid
diversity between its five genogroups (GI to GV) [10]. Up to 44%
amino acid diversity over VP1 is also observed within the
genogroups and has resulted in the further subgrouping of GI,
GII and GIII into 8, 17 and 2 genotypes, respectively [10]. VP1
exhibits the highest degree of sequence variability in the genome
[11,12]. It consists of three domains, namely the shell (S) domain
connected by a flexible hinge (P1 domain) to a protruding domain
(P2) [13]. The highly conserved S domain forms the backbone of
the capsid structure [13], while the moderately conserved P1
domain encodes the flexible hinge that connects the S and P2
domains. The protruding P2 domain possesses motifs that are
involved in binding to the host cell, and hence, the P2 domain is
responsible for the antigenicity of the virus [14,15].
The most clinically significant of the five genogroups is GII, as
it is the most prevalent human NoV genogroup detected and
more frequently associated with epidemics compared with other
genogroups. Of particular interest is GII genotype 4, (GII.4),
because this lineage accounts for 62% of all NoV outbreaks
globally [14,15] and has also caused all five major NoV
pandemics in the last decade (1995/1996, U5-95_US strain;
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2007, 2006b virus) [16,17,18,19]. The basis for the increased
epidemiological fitness [20] of the GII.4 strains, as determined by
its high incidence and ability to cause pandemics, is currently
unknown. Investigations with influenza indicate a link between
increased viral evolution and increased viral incidence [21,22].
However, because of the non-culturable nature of human NoV,
variations in rates of evolution have not been calculated for
different NoVs and consequently this has not been investigated as
a factor in determining viral incidence and epidemiological
fitness.
Replication efficiency and genetic diversity are both important
parameters in viral fitness [23]. The aim of this study was to
determine if these two parameters are contributing to the
increased epidemiological fitness of the GII.4 strains. Replication
efficiency and genetic diversity are primarily determined by
the viral RdRp, as it controls the rate new sequence is introduced
into the genome. Therefore using in vitro RdRp assays together
with bioinformatics, the replication efficiency, mutation rate and
rate of evolution of GII.4 viruses was compared with other
NoV GII genotypes. The results of this study suggest that, like
influenza A, the increased incidence of the pandemic GII.4
lineage may be a result of the combined influence of a high
mutation, replication and evolution rate which, together
culminate in an increased epidemiological fitness for the GII.4
strains.
Materials and Methods
NoV strains
Stool samples containing NoV were obtained from the
Department of Microbiology, Prince of Wales Hospital, Sydney,
Australia, with the exception of the stool specimen that contained
NoV/Mc17/01/Th (GenBank accession numbers AY237413).
This stool specimen was obtained from McCormic Hospital,
Chiang Mai, Thailand [16].
The six genetically diverse NoV strains used in this study
included: three GII.4 pandemic strains; NoV/Sydney 348/97/AU
(of the NoV/US95_96 GII.4 pandemic lineage) [16], NoV/
NZ327/06/NZ (NoV/2006a GII.4 lineage) [17] and NoV/
NSW696T/06/AU (NoV/2006b GII.4 lineage) [17]. Two
recombinant strains; NoV/Sydney C14/02/AU (GII.b ORF1
and GII.3 ORF2/3 [commonly referred to as GII.b/GII.3]) [16]
and NoV/Sydney4264/01/AU (GII.4 ORF1 and GII.10 ORF2/
3, [GII.4/GII.10]) [16], and a GII.7 NoV, NoV/Mc17/01/Th
associated with rare sporadic cases of gastroenteritis [24]. In this
study, the RdRp enzymes are referred to by their genotype, except
in the case of the GII.4 strains, which are referred to by their
pandemic name, eg. GII.4 2006b-RdRp (see Table 1). RdRps
from recombinant strains are indicated by an ‘r’ in front of the
nomenclature.
RNA extraction and cDNA synthesis
Viral RNA was extracted from 140 ml of 20% faecal suspension
using the QIAmp Viral RNA kit according to manufacturers’
instructions (Qiagen, Victoria, Australia). RNA was resuspended
in 50 ml of Baxter Steri-pour H2O and stored at 280uC. cDNA
synthesis was performed as described previously [16].
Table 1. Comparison of the replication accuracy and rate for NoV and HCV RdRps.
RdRpa Derivative Strain Kcat (s
21) Mutation Rate Rate of Evolution U
c (subs/genome)
in vitro nt subs/site
d sequence data nt subs/site/yr
Mean
d SD Mean
d SD Mean SD
GII.4 2006b NoV/Sydney696T/06/AU 0.209 0.054 9.06610
24 2.88610
24 3.9610
23 2.4610
24 6.80
rGII.4 NoV/Sydney4264/06/AU 0.168 0.024 8.34610
24 2.56610
24 Not done 6.26
GII.4 US95/96 NoV/Sydney348/97/AU 0.158 0.039 8.87610
24 4.42610
24 3.9610
23 2.4610
24 6.65
GII.4 2006a NoV/NZ327/06/AU 0.183 0.024 5.54610
24 3.84610
24 3.9610
23 2.4610
24 4.16
rGII.b NoV/SydneyC14/02/AU 0.155 0.093 1.53610
24 1.22610
24 2.4610
23 4.9610
24 1.15
GII.7 NoV/Mc17/02/Th 0.238 0.088 2.21610
25 4.58610
24 2.3610
23 1.5610
24 0.17
HCV/3a HCV/VRL69 0.003 8.06610
25 1.97610
23 1.42610
23 Not done 18.57
HCV/1b HCV/VRL75 0.003 1.06610
24 1.23610
23 1.14610
23 2.3610
22b N/A 11.57
aThe RdRps are named after their genotype except for the GII.4 pandemic strains which are named after their subcluster. Recombinants are indicated by an r before the
genotype.
bHVR1, published by Rispeter et al. [53].
cU: Number of mutations per viral replication round.
dThe mean and standard deviation of a triplicate data set.
doi:10.1371/journal.ppat.1000831.t001
Author Summary
Since 1995, norovirus has caused five pandemics of acute
gastroenteritis. These pandemics spread across the globe
within a few months, causing great economic burden on
society due to medical and social expenses. Norovirus, like
influenza virus, has over 40 genotypes circulating within
the population at the same time. However, it is only a
single genotype, known as genogroup II genotype 4
(GII.4), that causes mass outbreaks and pandemics. Very
little research has been conducted to determine why GII.4
viruses can cause pandemics. Consequently, we compared
the evolution properties of several pandemic GII.4 strains
to non-pandemic strains and found that the GII.4 viruses
were undergoing evolution at a much higher rate than the
non-pandemic norovirus strains. This phenomenon is
similar to influenza virus, where an increase in antigenic
drift has been associated with increased outbreaks. This
discovery has important implications in understanding
norovirus incidence and also the development of a vaccine
and treatment for norovirus.
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The full length capsid gene, P2 domain and RdRp regions were
amplified with specific primers (Table 2) using reverse transcrip-
tase - polymerase chain reaction (RT-PCR) methods described in
[17]. The amplified RdRp genes were cloned into pGEM-T Easy
vector (Promega, Wisconsin, United States).
DNA sequencing
Plasmids and PCR products were purified by PEG precipitation
and washed with 70% ethanol. Products were sequenced directly
on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City,
CA, US) using dye-terminator chemistry.
Construction of RdRp expression vectors and sequence
mutagenesis
pGEM-T Easy vectors containing 1736 bp from the 39 end of
ORF1 were purified using the Quantum prepH plasmid miniprep
kit (BioRad, California, United States) and used as template DNA
for the construction of expression vectors. Strain specific primers
incorporating restriction enzyme sites, were designed to amplify
the precise RdRp region of each strain (Table 2). PCR was
performed as described previously [17]. PCR products were
digested with their corresponding restriction enzymes and cloned
into the expression vector pTrcHis2A (Invitrogen, Mount
Waverley, Australia). Constructs containing the hepatitis C virus
(HCV) genotype 3a RdRp (pVRL69) and HCV genotype 1b
RdRp (pVRL75), were used as controls and have been described
previously [25].
Site directed mutagenesis of residue 291 in the GII.4 US95_96-
RdRp and the GII.4 2006a-RdRp was carried out with the
Stratagene Quickchange II mutagenesis kit, according to manu-
facturer’s instructions (Stratagene, La Jolla, United States). The
primers used to introduce the mutation into the plasmid are listed
in Table 2.
RdRp expression and purification
The NoV RdRps and control HCV RdRps were expressed in
Escherichia coli, as described previously [25], except expression of
the NoV RdRps was performed for 4 hr at 30uC. Purity was
checked by SDS-PAGE and the identity of the RdRp was
confirmed by western blot with an anti-six histidine antibody and
peptide sequencing performed by the Bioanalytical Mass Spec-
trometry Facility (University of New South Wales, Australia).
Recombinant RdRp was quantified with a Nanodrop ND-1000
Spectrophotometer (Nanodrop, Wilmington, United States).
RdRp kinetic measurements
Kinetic RdRp assays were performed in a final volume of 15 ml
and contained 20 mM Tris-HCl (pH 7.4), 2.5 mM MnCl2,5m M
DTT, 1 mM EDTA, 500 ng of homopolymeric C RNA template,
2 U RNasin (Promega), 4 mM sodium glutamate and increasing
concentrations of [
3H]-GTP (Amersham Biosciences, Little
Chalfont, UK) ranging from 2 mMt o6 0mM. Reactions were
initiated with the addition of 50 nM of RdRp and incubated for
9m i n sa t2 5 uC. The reactions were terminated by adding EDTA
to a final concentration of 60 mM, 10 mg herring sperm DNA and
170 ml of 20% (w/v) trichloroacetic acid. The incorporated
radionucleotides were precipitated on ice for 30 min and then
filtered through a 96 well GF/C unifilter microplate (Falcon,
Franklin Lakes, United States) by a Filtermate harvester (Packard
BioSciences, Melbourne, Australia). Using the harvester, the filters
were washed thoroughly with water and left to dry. The filter wells
were each filled with 25 ml of Microscint scintillation fluid
(Packard Biosciences) and radioactivity measured using a Packard
liquid scintillation counter (TopCount NXT; Packard Bioscienc-
es). Background measurements for each assay consisted of
reactions without RdRp and were subtracted from the count per
minute (CPM) values obtained for the individual enzyme assays.
Results were plotted and statistical analysis performed with the
Table 2. Oligonucleotide sequences designed and used in this study.
Primer Region Genotype Polarity
a Sequence 59-39
b
GV6 59 Capsid GII 2 TTRTTGACCTCTGGKACGAG
GV11 59 RdRp GII.4 US95_96 + CTAGGATCCAGGTGATGACAGTAAGGGAAC
GV12 39 RdRp GII.4 US95_96 2 TCAGAATTCGAYTCGACGCCATCTTCATTCTCA
GV21 39 Protease GII + GTBGGNGGYCARATGGGNATG
GV23 59 RdRp rGII.b, GII.4 2006a + CGCGGATCCAGGTGGCGACAACAAGGGAA
GV24 39 RdRp rGII.b, GII.4 2006a, GII.4 2006b 2 CCGGAATTCGATTCGACGCCATCTTCATTCACA
GV37 59 RdRp GII.7 + GACGAGCTCGGGAAATCAGGACCTT
GV38 39 RdRp GII.7 2 CCCAAGCTTGGATTCGACGCCATC
GV40 39 RdRp rGII.4 2 GCCTGCAGTACTTCGACGCCATC
GV43 P2 GII.4 + YAGCCCYGAYTTYTCRTT
GV44 P2 GII.4 2 ARRTGYTGNAYCCAYTCYTG
GV171 39 RdRp GII.4 2006b 2 CGCGGATCCAGGTGGTGACAGTAAGGG
GV172 59 RdRp rGII.4 + CGCGGATCCAGGCGGTGACAACAAAGG
GV194 K291T GII.4 US95_96 + GGTGACTTCACAATATCAATC
GV195 K291T GII.4 US95_96 2 GATTGATATTGTGAAGTCACC
GV196 T291K GII.4 2006a + GGTGACTTCAAAATATCAATC
GV197 T291K GII.4 2006a 2 GATTGATATTTTGAAGTCACC
a‘‘+’’ indicates that the oligonucleotide is a forward primer and ‘‘2’’ indicates that the oligonucleotide is a reverse primer.
bUnderlined sections indicate restriction enzyme sites.
doi:10.1371/journal.ppat.1000831.t002
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GraphPad Prism version 4.02 (GraphPad Software, San Diego,
CA).
Incorporation fidelity
An in vitro fidelity assay was developed to measure mutation
rates and was adapted from Ward et al. [26]. The RdRp assay was
performed using conditions described above with a homopoly-
meric C RNA template, except 82.1 pmoles of [
3H]UTP (2 mCi)
or [
3H]ATP (4 mCi) (Amersham Biosciences) were added (as the
non-complementary nucleotides) with an equimolar amount of
GTP (82.1 pmoles) (Promega) added as the complementary
nucleotide. The total amount of ribonucleotide incorporated was
calculated in a parallel experiment with the addition of 1 mCi
(164.2 pmoles) [
3H]GTP (Amersham Biosciences) as the correct
nucleotide. The assay was incubated for 50 min at 25uC. Error
frequency of the RdRp was determined by calculating the total
number (pmoles) of non-complementary ribonucleotides incorpo-
rated and dividing by the total number (pmoles) of [
3H]GTP
ribonucleotides incorporated.
Evolutionary analysis of NoV capsids
In order to determine the rate of evolution of the rGII.3, GII.3,
GII.4 and GII.7 capsids, the nucleotide sequences of ORF2 were
analysed. RNA capsid sequences used for the analysis included
eight from this study and 76 sequences from GenBank, with the
oldest strains available dating back to 1987. The strains used and
their GenBank accession numbers are listed in Text S1. The rate
of evolution (substitutions/nucleotide site/year) for GII.3, GII.b/
GII.3 GII.4 and GII.7 NoVs was determined by calculating the
number of nucleotide substitutions in ORF2 compared to an
ancestral strain and this was plotted against time [27]. The rate of
evolution was determined by linear regression with the program
GraphPad PRISMH version 4 and was equivalent to the gradient
of the line. Pairwise alignments of RNA sequences and
evolutionary distances between sequences were carried out using
the Maximum Composite Likelihood model in Mega 4.0 [28].
Bootstrapped trees (1000 data sets) were constructed using the
Neighbour-joining method, also with the program Mega 4.0.
In order to determine the amount of selection each genotype is
under, the average Ka/Ks ratio was calculated for each genotype’s
capsid gene (GII.4, GII.b/GII.3 and GII.7). The Ka/Ks ratio is a
measure of nonsynonymous amino acid changes compared to
synonymous (silent) changes. Ka/Ks.1 indicates that positive
selection is occurring. Ka/Ks=1 is interpreted as neutral
evolution and Ka/Ks,1 is indicative of negative or purifying
selection. The program Sliding Windows Alignment Analysis
Program (SWAAP) version 1.0.2 [29] was utilised. The Nei-
Gojobori model was used to calculate Ka and Ks values [30]. The
window size was set at 15 bp (5 aa) and the step size was 3 bp
(1 aa).
Protein modelling
Predicted secondary structure analysis of the RdRps and capsid
protein VP1 were performed by generating a Protein Data Bank
(PDB) file from the amino acid sequence in FastA format using
software on the CPHmodels 2.0 Server [31]. Three dimensional
structures were then generated from the PDB files with PyMol
[32].
Accession numbers
The GenBank accession numbers for the RdRp and capsid
genes described in this paper are listed in Text S1.
Results
In vitro analysis of NoV RdRps
NoV selection, expression and purification of
RdRps. To investigate the replication efficiency and mutation
rate for different NoV and control HCV RdRps, the RdRp
encoding region from six NoVs and two HCVs were cloned and
expressed. NoVs selected for this study included three pandemic
GII.4 strains; a non-pandemic recombinant virus with a GII.4
ORF1 (RdRp) and a GII.10 ORF2/3 (capsid) (GII.4/GII.10), a
second recombinant virus GII.b/GII.3, the second most prevalent
strain [16], and a rarely detected GII.7 strain. The RdRps were
expressed with additional N-terminal amino acids MDP and a C-
terminal myc epitope and hexahistidine tag. Approximately 1 to
3 mg of a 60 kDa and 68 kDa enzyme, for NoV and HCV,
respectively, were obtained and confirmed by mass spectrometry
(data not shown).
Replication rate. To determine the nucleotide incorporation
rate for the six NoV RdRps and the two HCV RdRps, the Kcat was
calculated with rGTP as substrate and poly C RNA as template
(Table 1). The fastest enzyme was GII.7-RdRp which had an
incorporation rate (Kcat) of 0.238 s
21, followed by the four GII.4
RdRps; 2006b-RdRp, 2006a-RdRp, rGII.4-RdRp and GII.4
US95_96-RdRp, with incorporation rates of 0.209 s
2160.054,
0.183 s
2160.024, 0.168 s
2160.024, 0.158 s
2160.039,
respectively. The slowest NoV enzyme was rGII.b-RdRp with
an incorporation rate of 0.155 s
2160.093 (Table 1). The two
HCV RdRps, HCV 3a-RdRp and HCV 1b-RdRp, had a much
lower incorporation rate compared to NoV RdRps with a Kcat
value of 0.003 s
21 for both (0.003 s
2168.06610
25 and
61.06610
25 for HCV 3a-RdRp and HCV 1b-RdRp,
respectively).
Increased incorporation rate associated with a
Lys291Thr mutation in the NoV RdRp. The first reported
GII.4 associated pandemic occurred in 1995/1996. It was not
until seven years later, in 2002, that a second GII.4 associated
pandemic occurred. Since the 2002 pandemic, however, three
more GII.4 associated pandemics have arisen (2004, 2006 and
2007). Interestingly, an increase in incorporation rate was
observed in post 2002 pandemic RdRps (2006a-RdRp and
2006b-RdRp) compared to pre 2002 GII.4 RdRps (US95_96-
RdRp [1995], rGII.4-RdRp [2001]) (p-value 0.022, Table 1).
However, comparison of the mutation rates showed no differences
between pre and post 2002 GII.4 RdRps.
To identify specific residues associated with RdRps that had a
higher incorporation rate, an alignment of the amino acid
sequence of the six NoV RdRps was performed (Fig. 1). The
three NoV RdRps with slower incorporation rates (GII.4
US95_96-RdRp, rGII.4-RdRp and rGII.b-RdRp) had a Lys at
residue 291 whereas the three RdRps with faster incorporation
rates had either a Thr (2006a-RdRp and 2006b-RdRp) or a Val
(GII.7-RdRp) (Fig. 1) (mutation numbered according to Lordsdale
virus RdRp, GenBank accession number X86557). No other
amino acid variation was unique to the three faster enzymes
(Fig. 1). A database search of GenBank for all full length NoV GII
RdRp sequences available (accessed 9
th Nov, 2009) revealed the
Thr291 residue was only identified in GII.4 strains isolated during
or after 2001. In fact, the Lys291 mutation appears to have
become fixed in the GII.4 pandemic lineage after its initial
appearance in 2001.
To analyse the affect of the Lys291Thr mutation on the
incorporation rate of the GII.4 RdRps, two mutant enzymes were
made: GII.4 US95_96
K291T-RdRp and GII.4 2006a
T291K-RdRp.
Specifically, the US95_96-RdRp 291Lys residue was mutated to a
NoV Evolution
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kinetic activity of the two mutant RdRps was then compared to
the wildtype enzymes (Fig. 2). The Lys291Thr mutation increased
US95_96-RdRp activity by 20.2% (US95_96
291K-RdRp:
0.168 s
2160.018 [n=6], US95_96
291T-RdRp: 0.202 s
2160.019
[n=6)] p-value=0.008), whereas, the reverse Thr291Lys muta-
tion decreased activity of the 2006a-RdRp by 22.2% (2006a
291T -
RdRp: 0.351 s
2160.037 [n=3], 2006a
291K -RdRp:
0.273 s
2160.020 [n=4], p-value=0.029) (Fig. 2).
In vitro analysis of the RdRp mutation rate. A high
mutation rate (10
23 to 10
25 misincorporations per site) has been
reported for most viral RdRps using either cell culture studies or
biochemical analysis (reviewed in [20]). The mutation rate of the
NoV RdRp has however, not been studied. Consequently, the
present study developed an in vitro fidelity assay to enable direct
comparison of the mutation rate of RdRps which could easily be
applied for use with all non-culturable and culturable RNA
viruses. Using this assay the mutation rate (substitutions per
nucleotide site) for a transversion event (incorporation of UTP into
a poly C RNA template) was calculated for all six NoV RdRps and
for two control HCV RdRps (Table 1). The two HCV RdRps had
the highest mutation rates of all eight enzymes at 1.60610
23
(60.52610
23) substitutions per nucleotide site (Table 1). The
mutation rates of the NoV RdRps were approximately one to two
orders of magnitude lower than HCV (Table 1). The four GII.4
RdRps, US95_96-RdRp, rGII.4-RdRp, 2006a-RdRp and 2006b-
RdRp, had similar mutation rates at 8.87610
24, 8.34610
24,
5.54610
24 and 9.06610
24 substitutions per nucleotide site,
respectively, and were higher than the remaining two NoV
RdRps, rGII.b-RdRp (1.53610
24 substitutions per nucleotide site)
and GII.7-RdRp (2.21610
25 substitutions per nucleotide site)
(Table 1).
The in vitro fidelity assay above examined transversion events,
which are reported to occur at a lower frequency than transition
events [20]. To confirm that the GII.4 enzymes have a higher
mutation rate using different substrates the transition mutation
rate was examined for two enzymes, US95_96-RdRp and GII.7-
RdRp. Accordingly, the frequency of transition events (ATP into a
poly C RNA template) was 1.5 and 1.7 fold higher than UTP
(Table 1), for US95_96-RdRp, 1.30610
2361.08610
23 (n=3)
and GII.7-RdRp, 3.71610
2561.21610
25 (n=3), respectively.
This increase was not found to be significantly different from the
transversion mutation rate (p-value=0.5).
The in vitro transversion mutation rates were used to estimate the
number of substitutions per viral genome replication event (U) for
each RdRp [33] (Table 1). U equals the RdRp error rate
multiplied by the genome size (7555 bp for GII.4 and GII.7,
7579 bp for GII.3 NoV and 9425 bp and 9408 bp for HCV 3a
and 1b, respectively). The two HCV RdRps had the highest U
values with an average of 15.0764.96 substitutions per genome
replication event (Table 1). The NoV RdRps had lower U values
than HCV, with an average of 5.9761.96 substitutions per
Figure 1. Comparison of the amino acid sequence of the six NoV RdRps used in this study to other representative GII strains. The top
six sequences are the RdRps characterised in this study (GII.4 US95_96, rGII.4, GII.4 2006a, GII.4 2006b, GII.7 and rGII.b). The remaining 19 strains are
reference strains and are named according to their GII genotype followed by their year of isolation (GII.4 strains only) and then their strain name. The
alignment illustrated that a K291T substitution first appeared in the GII.4 lineage after 2001 and was unique for the GII.4 pandemic strains.
doi:10.1371/journal.ppat.1000831.g001
Figure 2. The effect of mutations at residue 291 on NoV GII.4
RdRp kinetic activity. A K291T mutation in wildtype (W+) NoV/
US95_96-RdRp lead to a 20.2% increase in RdRp activity. Open bars
show US95_96
291K-RdRp: 0.168 s
2160.018 [n=6], US95_96
291T-RdRp:
0.202 s
2160.019 [n=6)], p-value=0.008. Whereas, a mutation T291K
lead to a 22.2% reduction in activity for NoV/2006a-RdRp compared to
the wildtype K291T. Hashed bars show 2006a
291T-RdRp:
0.351 s
2160.037 [n=3], 2006a
291K-RdRp: 0.273 s
2160.020 [n=4], p-
value=0.029.
doi:10.1371/journal.ppat.1000831.g002
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substitutions per genome replication event for rGII.b-RdRp and
0.17 substitutions per genome replication event for GII.7-RdRp
(Table 1).
Bioinformatic analysis of NoV capsid evolution
Strain selection. The in vitro fidelity assay described above
provides a format to directly compare the mutation rate of viral
RdRps. To achieve a second independent comparison of the
mutation rate for selected NoV GII genotypes, sequence data
from four lineages was gathered and substitution rates were
calculated by analysing sequence variation within ORF2, the
capsid gene, over time. The capsid gene was chosen for two
reasons; firstly, this region has the most sequence data available
in nucleotide databases and secondly, ORF2 encodes VP1 which
contains the host receptor binding domains that determine
antigenicity of the virus and therefore provide the best indication
of host driven evolution [14]. The four lineages examined were
GII.4, GII.7, GII.3 and GII.b/GII.3 (Fig. 3A to C). The capsid
lineage derived from the recombinant strain GII.b/GII.3 were
analysed independently of the wildtype GII.3 lineage in order to
examine the influence of the RdRp (ORF1) on rate of evolution
of VP1.
The GII.4 capsid analysis included 54 GII.4 strains circulating
between 1987 and 2008, with the oldest NoV strain MD134-7/
87/US defined as the root (Fig. 3A). The GII.3 capsid analysis
included 11 GII.b/GII.3 and 14 GII.3 strains circulating between
1987 and 2006, with MD134-10/87/US defined as the ancestral
strain (Fig. 3B). Phylogenetic analysis indicated that the GII.b/
GII.3 recombination event occurred prior to 2001 and the new
recombinant virus subsequently evolved away from the wildtype
GII.3 strains (Fig. 3B). Only five GII.7 strains with full length
capsid sequence, three of which were generated in this study, were
available for analysis. The five GII.7 strains were isolated between
1990 and 2007 and Leeds/90/UK was defined as the ancestral
strain in this study (Fig. 3C).
Rate of evolution. Analysis of the sequence data revealed
that GII.4 NoVs had the highest rate of evolution at 3.9610
23
nucleotide substitutions/site/year (equivalent to 6.3060.39
nucleotide changes/capsid/year) (r
2=0.84, n=54, p,0.0001)
(Fig. 4). The rates of evolution for the wildtype GII.3 strain, the
GII.b/GII.3 recombinant strain and the GII.7 strain were lower at
1.9610
23, 2.4610
23 and 2.3610
23 nucleotide substitutions/site/
year, respectively (r
2=0.28, n=14, p=0.004; r
2=0.63, n=11,
p,0.001 and r
2=0.99, n=5, p=0.002) (Fig. 4). Statistical
analysis of the data suggested that the GII.4 rate of evolution
was significantly higher (p,0.010) than the GII.b/GII.3, GII.3
and GII.7 rates of evolution.
The amount of selection (purifying and positive selection)
occurring in the capsid gene from the GII.4, GII.b/GII.3 and
GII.7 strains was examined by calculating the Ka/Ks ratio for each
genotype individually. The Ka/Ks ratio generated for the GII.4
strains was higher (0.091260.0322) than that of the GII.b/GII.3
strains (0.086260.495) and the GII.7 strains (0.043760.0235).
Evolution hotspots within the NoV capsid. Sequence
alignments of the capsid P2 domain from 54 GII.4 strains
supported previously published data that there are 15 major
amino acid residues which vary between each GII.4 pandemic
cluster. These amino acids include 296 to 298, 333, 340, 355, 365,
368, 372, 393 to 395, 407, 412 and 413 (supplementary Fig. S1A)
[4,15]. Examination of the position of these 15 residues on the
predicted secondary structure revealed that they clustered on the
surface of six exposed loops of the P2 domain (Fig. 5). Similar
amino acid alignments for GII.7 and GII.3 revealed there were
three and six hypervariable sites which clustered onto two and four
exposed loops of the P2 domain, respectively (supplementary Fig.
S1B and C). A structural alignment revealed that the
hypervariable residues in the GII.3 and GII.7 occupied
overlapping spatial sites compared to the hypervariable residues
in GII.4 described above (Fig. 5). In particular, the site occupied
by 296 to 298, 365, 368, 372 in GII.4 corresponded to 310 and
312 in GII.3, 333 in GII.4 corresponded to 389 in GII.3, 393 to
395 in GII.4 corresponded to 392 and 404 in GII.3 and 355 in
GII.4 corresponded to 395 in GII.3 (Fig. 5). GII.7 only had two
variable regions, 352/354 and 396, and these corresponded to
similar spatial orientation as the GII.4 variable sites 296 to 298,
365, 368, 372, and 393 to 395, respectively (Fig. 5).
Discussion
Over the last decade five NoV pandemics have occurred
approximately every two years and all pandemics have been
associated with a single NoV genotype, GII.4 [16,17,19,34]. The
reason for the predominance of the GII.4 strains has been the
subject of much speculation but is currently unknown primarily
due to a limited understanding of NoV population dynamics and
evolution [4,15,35].
Studies with other RNA viruses indicate that viral fitness is
dependent on many factors, such as, viral mutation, replication
efficiency, population size and host factors (reviewed in [2]). To
date progress has been made in understanding the role host factors
have on NoV prevalence with several studies indicating that
variations in viral docking to the blood group antigens may affect
infectivity of individuals within a population (reviewed in [36]). In
particular, GII.4 viruses bind to all blood group antigens, whereas,
GII.1 and GII.3 viruses bind fewer blood group antigens and this
could account for higher prevalence of GII.4 viruses [36]. This
paradigm however remains controversial, especially for GII NoV,
as not all studies show an association between blood group
antigens and clinical infection [37,38,39].
Apart from the host/viral interaction, no other factors have
been affiliated with NoV fitness. Recent studies performed with
poliovirus have shown that an increase in fidelity leads to less
genetic diversity and subsequently a reduction in viral fitness and
pathogenesis because of a reduced adaptive capacity of the virus
[40,41]. It has been hypothesised that viruses are fitter if they are
able to produce a more robust (diverse) population (reviewed in
[42,43,44]). In the current study we examined whether there was a
link between epidemiological fitness, as defined by their incidence,
and the rate and accuracy of viral replication.
In the present study error rates were assessed directly by
examining the mutation rate of the viral RdRp and by analysing
the rate of evolution for selected GII lineages. Our results are
consistent with mutation rates for the poliovirus RdRp [26] and
retrovirus reverse transcriptases [45], which range between 10
23
to 10
25 (Table 1). The more prevalent GII.4 strains had a 5 to 36-
fold higher mutation rate compared to the less frequently detected
GII.b/GII.3 and GII.7 strains, as determined by in vitro enzyme
assays. Consistent with this, the rate of evolution of the capsid was
on average 1.7-fold higher in GII.4 viruses compared to GII.3,
GII.b/GII.3 and GII.7 viruses. The GII.4 capsids also had a larger
Ka/Ks ratio than the GII.b/GII.3 and GII.7 strains suggesting
that the increased incidence/epidemiological fitness of the GII.4
strains maybe through greater antigenic drift, a consequence of the
higher mutation rate of the GII.4 RdRp.
The mutation rates for the control HCV RdRps (average of
1.6610
23 substitutions per nucleotide site, Table 1) were 2-fold
higher compared to the GII.4 RdRps. Evaluation of previously
NoV Evolution
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(HVR1) within the envelope 2 glycoprotein (E2) were also higher
(6–fold) than the NoV GII.4 rates of evolution calculated in this
study [46] (Table 1). HVR1 was chosen for comparison because,
like the NoV capsid gene, it is the most variable region in the
genome and under the greatest immune selection. Mutation rate
Figure3. Phylogenetic analysisoftheaminoacid sequenceofthe P2domainfromGII.4 (A), GII.b/GII.3andGII.3 (B) andGII.7 (C) strains
circulating between 1987 and 2008. The phylogenetic tree was generated using the Neighbour-Joining method [51] by comparison of the P2 amino
acid sequence (152 aa for GII.4 and 7, and 160 aa for GII.3) obtained for 84 NoV strains. GenBank accession numbers are included in the figure and follow
the strain name. The percentage bootstrap values in which the major groupings were observed among 1000 replicates are indicated. The branch lengths
are proportional to the evolutionary distance between sequences and the distance scale, in nucleotide substitutions per position, is shown.
doi:10.1371/journal.ppat.1000831.g003
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indirectly related due to the increased complexity of evolution in
vivo [20]. However, in this study we did find a common trend
between the two different measurements of diversity with HCV
displaying the highest diversity rate for both measurements
compared to NoV.
Interestingly, the majority of non-synonymous mutations in the
P2 domain for all three NoV genotypes were localised to six
common structural sites. These six hypervariable regions within
the P2 domain were consistent with hypervariable sites for GII.4
capsids already identified in other studies [4,19]. We demonstrated
that GII.7 and GII.3 viruses shared two and four common
hypervariable sites, respectively, with GII.4 viruses (Fig. 5).
Substitutions at one of these sites (residue 395) have been shown
to alter GII.4 strains antigenic profiles [4]. Localization of the
hypervariable sites to common regions on the surface of the P2
domain suggests that these regions are likely to be under immune
pressure possibly from a neutralizing antibody response [39]. The
lower number of amino acid changes at these sites for viruses with
a GII.3 capsid may explain why GII.b/GII.3 is predominantly
associated with gastroenteritis cases in children [47]. This suggests
that GII.b/GII.3 viruses are not as efficient at escaping herd
immunity compared to GII.4 strains and therefore only hosts
immunologically naı ¨ve to GII.3 infection are susceptible. Similar-
ly, we propose that the low prevalence of the GII.7 strain is also a
consequence of a low mutation rate in the RdRp resulting in
limited antigenic drift and an inability to escape herd immunity.
Apart from mutation rate, replication rate is considered to be
another major determinant in viral fitness [48]. Replication rates
are important because an increased replication rate would produce
a larger heterogenous population than a slower replicating virus in
the same unit of time, given the same mutation rate. Interestingly,
the RdRps from the recent 2006 GII.4 pandemic strains had a
higher nucleotide incorporation rate than the recombinant GII.4
RdRp and the US95/96-like pandemic GII.4 RdRp, which could
be associated with a point mutation in the RdRp (Thr291Lys).
Residue 291 is located in the finger domain, which is comprised of
five b sheets that run parallel and strongly interact with each other.
The innermost of these five b sheets contains motif F which
interacts directly with incoming nucleotides [49]. Therefore, it is
plausible that substitutions at residue 291 affects the orientation of
Figure 4. Rate of evolution for the GII.4, GII.7, GII.b/GII.3 and
GII.3 strains. The rate of evolution for each genotype was determined
by calculating the number of nucleotide substitutions in ORF2
compared to the oldest strain in each lineage. The number of changes
was then plotted against the year of that strains detection. The rate of
evolution was equivalent to the gradient of the line (GII.4=6.3060.39,
r
2 =0.84; GII.b=4.0360.80, r
2 =0.68; GII.3=3.0960.95, r
2 =0.49;
GII.7=3.8260.25, r
2=0.99) divided by the length of the capsid gene
(1623 bp for GII.4 and GII.7, and 1647 bp for GII.3 and GII.b/GII.3).
doi:10.1371/journal.ppat.1000831.g004
Figure 5. Hypervariable residues in GII.3, GII.4 and GII.7 are localised to common regions on the surface of the capsid P2 domain.
The structure of the GII.4 P1 and P2 domain was solved previously (PDB ID 2OBS [52]) while the structure of the P domain was predicted for GII.3 and
GII.7 in this study. The location of the hypervariable residues are indicated numerically and are coloured pink for all three genotypes. Residues
occupying similar regions are depicted by the same coloured circle. The previously published hypervariable residues in the P2 domain of GII.4 were
localised to six main regions on the surface of the P2 domain [4,15]. GII.3 had hypervariable residues in four of these regions and GII.7 had
hypervariable residues in two of these regions.
doi:10.1371/journal.ppat.1000831.g005
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subsequently alters the binding affinity to the incoming nucleotide.
Fixation of the Thr291Lys point mutation in the GII.4 lineage
after 2001 has been paralleled with a reduction in the period of
stasis between the emergence of new antigenic variants [4].
Alterations in residue 291 after 2001 could have led to an increase
in the rate of evolution of GII.4 strains by increasing the
replication rate, however this did not seem to have an effect on
mutation rate (Table 1). High replication rates did not always
correlate with epidemiological fitness as the NoV strain, GII.7,
had the highest incorporation rate but is considered to be the least
fit due to it having the lowest incidence. Therefore, this study
suggests mutation rate in combination with a high replication rate
are key determinates in epidemiological fitness.
Influenza research also indicates a relationship between rate of
evolution and epidemiological fitness (reviewed in [21]). New
antigenic influenza A variants arise every one to two years and
cause more annual epidemics than influenza B, as well as the more
devastating pandemics [21]. Once a population has accumulated
mass herd immunity to a virus the virus is forced to alter its
antigenic determinants, a possibility for viruses with poor fidelity
and fast replication rates, or face extinction [50], whereas, viruses
such as influenza B, which have higher fidelity and slower
antigenic change, are more often associated with sporadic cases
[21]. In this study a parallel can be seen in the epidemiology
between NoV and influenza, in particular between GII.b/GII.3
viruses and influenza B and GII.4 viruses and influenza A.
In summary, this study supports the hypothesis that epidemi-
ological fitness is a consequence of the ability of the virus to
generate genetic diversity, as the NoV pandemic GII.4 strains
were associated with an increased replication and mutation rate.
Therefore, it would seem that GII.4 viruses, as opposed to GII.b/
GII.3 and GII.7 viruses, have reached a balance in their
replication rate and mutation rate that is better suited to viral
adaptation. In contrast, it would seem that the GII.7 lineage,
despite having a high replication rate, has a low mutation rate that
limits its adaptation and therefore its incidence. It is important to
improve our understanding of the mechanisms underlying NoV
epidemiological fitness as future pandemics are expected.
Supporting Information
Text S1 GenBank accession numbers used in this study.
Found at: doi:10.1371/journal.ppat.1000831.s001 (0.04 MB PDF)
Figure S1 Alignment of the amino acid sequences of the P2
domain from A) GII.4 strains circulating between 1987 and 2006,
B) GII.3 strains circulating between 1987 and 2006, and C) GII.7
strains circulating between 1990 and 2008. Sequences include the
152 aa of the P2 domain from 54 GII.4 strains and 5 GII.7 strains,
and 160 aa of the P2 domain from 25 GII.3 or GII.b/GII.3
strains. Sequences were aligned using Mega 4.0. The NoV
sequences included in the alignment are the same as in Fig. 4.
Found at: doi:10.1371/journal.ppat.1000831.s002 (6.93 MB
TIF)
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